Presbyopia

Technical details, communication style key to presbyopia-correcting IOL journey.

George Waring, MD, discusses the findings of a retrospective study on Allergan’s AGN-190584 for the treatment of presbyopia.

Ben Bergo, CEO of Visus Therapeutics, gives a company update on the company's presented phase 2 data, and what's next in the pipeline.

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

Study reviews mechanisms of action of pilocarpine, carbachol, and brimonidine.

For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.

Ophthalmologists have several options at their disposal for the treatment of presbyopia, according to Elizabeth Yeu, MD, a partner at Virginia Eye Consultants and an assistant professor at Eastern Virginia Med¬ical School in Norfolk. Speaking recently at the virtual 2022 Toronto Cataract Course, Yeu noted that innovation is advancing in presbyopia correction.

According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.

April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.

The company has dosed the first patients in a Phase 3 trial evaluating the safety and efficacy of Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.

Study investigators compared 2 novel lens designs using data obtained from 19 investigational sites in Australia, Canada, Spain, and the UK

Presbyopia-correcting drops represent a whole new product category—one with a lot of upsides for clinicians who want to help their patients see well at all distances.

The future of this age-related condition is bright and in focus.

The approach seems to provide high levels of spectacle independence and patients' satisfaction, with limited complications associated.

Spectacle independence is not the main factor that determines patients’ lens selections, according to study investigators.

The approval will allow LensGen to move forward with the IDE pivotal trial with the ultimate goal of seeking premarket approval in the United States.

This model can restore visual function and provide good intermediate and near vision in both photopic and mesopic conditions.

The VIVID study focuses on three novel topical ophthalmic formulations under investigation for the treatment of presbyopia

Lens combines diffractive multifocal and extended depth-of-focus properties.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

Demographics show high demand for solutions beyond eyeglasses.